Navigation Links
MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy

TUCSON, Ariz., Dec. 19, 2011 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) has awarded $750,000 to Summit PLC, a UK biotechnology company, to continue development of an experimental drug that may become a viable treatment for boys with Duchenne muscular dystrophy (DMD).

The funding comes from MDA Venture Philanthropy (MVP), a part of MDA's translational research program.

DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles.  Caused by mutations in the gene that makes dystrophin, a protein that normally protects muscle cells and keeps them intact, DMD eventually affects all voluntary muscles, and the heart and breathing muscles.  DMD affects 1 in 3,500 boys with an estimated patient population of 50,000 in the developed world.    

Summit's SMT C1100 is an experimental compound designed to increase the muscle protein utrophin, which is a naturally-occurring protein that has a similar function to dystrophin.  Investigators are confident that if utrophin could be upregulated sufficiently, it could act as a substitute for the missing dystrophin in DMD to help maintain healthy muscles.

"A long-time champion for utrophin upregulation as a promising therapeutic strategy for treating Duchenne muscular dystrophy, MDA is pleased Summit soon will be testing a new formulation of SMT C1100 in a human clinical trial," said Valerie Cwik, M.D. Executive Vice President Research and Medical Director for the Muscular Dystrophy Association. 

"This is a vital step toward knowing definitively whether utrophin can successfully stand-in for the missing dystrophin protein that MDA-funded investigators identified as the underlying cause for this form of muscular dystrophy," Cwik added.

Barry Price, Ph.D., Executive Chairman of Summit said:  "The new clinical study to be conducted on SMT C1100, a drug discovered and developed by our scientists is an important initiative.  We believe SMT C1100 has the potential to treat all DMD patients and provide benefit for them and their families."

A previous trial of an earlier SMT C1100 formulation on healthy volunteers by another biotech firm in California deemed the compound to be safe and well-tolerated.  However, variable blood concentrations were generated with only some individuals achieving expected therapeutic levels in the bloodstream.

About Utrophin Upregulation
Utrophin is a naturally-occurring protein that has a similar function to dystrophin.  Utrophin is produced during fetal development but its production is switched off in adults.  If utrophin production could be maintained, it could act as a substitute for the missing dystrophin to maintain the healthy function of muscles.  One method of turning utrophin production back on is through pharmacological means.  Utrophin upregulation has the potential to be beneficial to all DMD patients regardless of their specific genetic mutation and is also expected to be complementary to other therapeutic approaches in development.

About Muscular Dystrophy Association
MDA is the nonprofit agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research.  The Association also provides comprehensive healthcare and support services, advocacy and education.

Long the world's leading non-governmental funder of muscular dystrophy research and health care services to affected individuals, MDA has played a pioneering role in utrophin-related research since 1996 (investing nearly $16 million to help develop this promising therapeutic pathway).   Presently, MDA active grants include 102 focused on Duchenne muscular dystrophy, representing a multi-year investment of close to $35 million.

In addition to annually funding some 300 research teams worldwide, MDA maintains a national network of some 200 hospital-affiliated clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides extraordinary local summer camp opportunities for thousands of youngsters fighting progressive muscle diseases.  Known globally for its Labor Day Telethon, MDA is the first nonprofit to receive a Lifetime Achievement Award from the American Medical Association "for significant and lasting contributions to the health and welfare of humanity."  To learn more, watch the award-winning "Make a Muscle, Make a Difference" PSA, visit or follow MDA on Facebook or Twitter.

About Summit
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin™ technology platform for the discovery of new medicines and a portfolio of drug program assets.  Seglin™ technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches and it is expected to have broad use in major disease areas.  Summit's program portfolio consists of a number of drug programs targeting areas of high unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at

Journalists interested in the latest guidelines for reporting on people living with disabilities may want to visit the latest recommendations.

SOURCE Muscular Dystrophy Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Digital Assent Wins Back-to-Back Spirit of Endeavor Awards, This Year for Top "Emerging Technology Company"
2. WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards
3. GHX Calls on Member Community to Nominate Healthcares Most Impactful Business Partners for GHXcellence Awards
4. The Food and Drug Law Institute to Present Distinguished Service and Leadership Awards to Andersen, Autor, Brady, Thirolf
5. BRAVE Awards Recipients Announced
6. Novation Awards ICU Medical, Inc. a New Contract to Supply Members With a Complete Line of Clinically-Preferred Critical Care Products
7. Occupy Oakland Business Fraud Verdict: Oakland Jury Awards $9 Million Against Multi-National Corporation for Business Fraud and Breach of Contract
8. Glenmark Wins Two Prestigious Global Recognitions at SCRIP Awards 2011
9. UBM Canons 2012 Medical Design Excellence Awards Calls for Entries
10. GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards
11. Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):